Related Experiment Video
Updated: Mar 26, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
Published on: July 20, 2022
Successful Treatment of a Pacemaker Infection with Intraperitoneal Daptomycin
Anne B Taegtmeyer1, Nina Kononowa2, Dominique Fasel3
1Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland.
Abstract:
We investigated the pharmacokinetics of intraperitoneal administration of daptomcyin in a peritoneal dialysis (PD) patient treated for a pacemaker infection with Staphylococcus epidermidis. After initial start of intravenous daptomycin at 9 mg/kg body weight every 48 hours, the therapy was switched to intraperitoneal administration of 5.3 mg/kg body weight in 1 L icodextrin 7.5% with a dwell time of 12 hours overnight every 48 hours. Therapeutic drug monitoring (TDM) was performed at 4 hours and 24 hours after dose administration. Due to high peak concentration above target peak concentration, the dose was reduced to a final maintenance dose of 3.2 mg/kg body weight. Data from this single case suggest that serum drug concentration above the minimal inhibitory concentration (MIC) can be easily achieved with intraperitoneal administration of daptomycin every 48 hours even with a lower dose, as recommended for the intravenous administration, but measurement of serum concentration and dose adjustments are mandatory in such cases.
Insights
Intraperitoneal daptomycin effectively treats infections in peritoneal dialysis patients. Careful therapeutic drug monitoring and dose adjustments are crucial for achieving optimal daptomycin serum concentrations.
Area of Science:
- Pharmacology
- Nephrology
- Infectious Diseases
Background:
- Daptomycin is a crucial antibiotic for treating Gram-positive infections, including those caused by Staphylococcus epidermidis.
- Peritoneal dialysis (PD) patients present unique challenges for antibiotic dosing due to altered drug pharmacokinetics.
- Intraperitoneal (IP) administration offers a potential alternative route for antibiotic delivery in PD patients.
Observation:
- A single PD patient with a pacemaker infection was treated with intravenous, then intraperitoneal daptomycin.
- The initial IP daptomycin dose of 5.3 mg/kg every 48 hours resulted in supratherapeutic peak serum concentrations.
- Therapeutic drug monitoring (TDM) guided a dose reduction to 3.2 mg/kg every 48 hours.
Findings:
- Intraperitoneal daptomycin administration achieved serum concentrations above the minimal inhibitory concentration (MIC) in a PD patient.
- Lower IP daptomycin doses may be sufficient compared to standard intravenous recommendations.
- Serum drug concentration monitoring and dose adjustments are essential for safe and effective IP daptomycin therapy.
Implications:
- Intraperitoneal daptomycin is a viable option for treating PD patients with specific infections.
- Pharmacokinetic variability necessitates individualized dosing and TDM for IP daptomycin.
- This case highlights the importance of adapting antibiotic strategies for PD patients to ensure therapeutic efficacy and safety.
Related Concept Videos
Endocarditis III: Medical Management
Pericarditis III: Medical Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Diphtheria
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Endocarditis IV: Nursing Management

